Recent advances in the management of juvenile systemic sclerosis

References

• Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res. 2010;62:213–218.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Zhavania M, Birdi N, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology. 2000;39:556–559.
   PubMed Web of Science ®Google Scholar
• Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood. Clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54:3971–3978.
   PubMed Web of Science ®Google Scholar
• Martini G, Vittadello F, Kasapçopur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatol. 2009;48:19–122.
   Web of Science ®Google Scholar
• Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League Against Rheumatism Provisional classification criteria for Juvenile Systemic Sclerosis. Arthritis Rheumatology. 2007;57(2):203–212.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2013;72:1747–1755.
   PubMed Web of Science ®Google Scholar
• Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features and survival in comparison with adult onset disease. J Rheumatol. 2006;33:1004–1013.
   PubMed Web of Science ®Google Scholar
• Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am. 2008;34:239–255.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nihtyanova S, Wierk A, et al. Characteristics of patients with juvenile onset systemic sclerosis in an adult single centre cohort. J Rheumatol. 2010;37:2422–2426.
   PubMed Web of Science ®Google Scholar
• Zulian F, Cuffaro G, Sperotto F. Scleroderma in children: an update. Curr Opin Rheumatol. 2013;25:643–650.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902–3912.
   PubMed Web of Science ®Google Scholar
• Valentini G, Marcoccia A, Cuomo G, et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken). 2014;66:1520–1527.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40:1984–1991.
   PubMed Web of Science ®Google Scholar
• Silman A, Akesson A, Newman J, et al. Assessment of functional ability in patients with scleroderma: proposed new disability assessment instrument. J Rheumatol. 1998;25:79–83.
   PubMed Web of Science ®Google Scholar
• Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol. 2000;12:545–548.
   PubMed Web of Science ®Google Scholar
• La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum. 2012;64:4143–4150.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Boracchi P, Gualtierotti R, et al. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: a EUSTAR exploratory study. Microvasc Res. 2015;102:19–24.
   PubMed Web of Science ®Google Scholar
• Gerhold K, Becker MO Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications. Clin Exp Rheumatol. 2014;32:83–8
   Web of Science ®Google Scholar
• M Cappella, R Culpo, M Sprocati, et al. Infrared thermography after cold challenge: validation in diagnosis of Raynaud's phenomenon in pediatric age. Ann Rheum Dis. 2015;74:189.
   Google Scholar
• Rodeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med. 1983;308:880–883.
   PubMed Web of Science ®Google Scholar
• Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis (Review). The Cochrane Library. 2007;1:1–16.
   Google Scholar
• Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford). 2004;43:229–233.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Denton CP, Furst, DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32–38.
   PubMed Web of Science ®Google Scholar
• Seibold JR, Matucci-Cerinic M, Denton CP, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis. 2006;65(Suppl II):90.
   Google Scholar
• Shimizu M, Hashida Y, Kazuyuk U, et al. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis. Pediatr Cardiol. 2011;32:1040–1042.
   PubMed Web of Science ®Google Scholar
• García De La Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, et al. Long-term experience of bosentan for treating ulcers. Rheumatology. 2008;47:464–466.
   PubMed Web of Science ®Google Scholar
• Valentini G, D’Angelo S, Della Rossa A, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003;62:904–905.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Wierk A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology (Oxford). 2006;45:76–78.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364–372.
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351–1358.
   PubMed Web of Science ®Google Scholar
• Zulian F, Martini G, Vallongo C, et al. Methotrexate in juvenile localized scleroderma: A randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63:1998–2006.
   PubMed Web of Science ®Google Scholar
• Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology. 2013;52(6):1095–1100.
   PubMed Web of Science ®Google Scholar
• Arif T, Masood Q, Singh J, et al. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 2015;15:24.
   PubMed Web of Science ®Google Scholar
• Tauber M, Avouac J, Benahmed A, et al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol. 2014;32:S-82-7.
   PubMed Web of Science ®Google Scholar
• Bharadwaj S, Tandon P, Gohel T, et al. Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma. J Clin Gastroenterol. 2015;49:559–564.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Bussone G, Berezné A, et al. Scleroderma renal crisis. J Rheumatol. 2014;41(6):1040–1048.
   PubMed Web of Science ®Google Scholar
• Hudson M, Baron M, Tatibouet S, et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43(5):666–672.
   PubMed Web of Science ®Google Scholar
• Quartier P, Bonnet D, Jean-Christophe F, et al. Severe cardiac involvement in children with sistemic sclerosis and myositis. J Rheumatol. 2002;29:1767–1773.
   PubMed Web of Science ®Google Scholar
• Wozniak J, Dabrowski R, Luczak D, et al. Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma. J Rheumatol. 2009;36(1):191–196.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Reyna TS, Moleros-Guzman M, Hernandez-Reyes P, et al. Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. Rheumatol. 2015;54:647–654.
   PubMed Web of Science ®Google Scholar
• Thuny F, Lovric D, Schnell F, et al. Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. Radiology. 2014;271:373–380.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Yokoe I, Hirano M, et al. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol. 2009;36(1):106–112.
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Reffo E, et al. Magnetic resonance and echocardiographic strain rate imaging for the early detection of cardiac involvement in juvenile systemic sclerosis. In: (Abstract) American College of Rheumatology (ACR) annual meeting. San Francisco; 2015.
   Google Scholar
• Vignaux O, Allanore Y, Meune C, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005;64:1268–1273.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Meune C, Vignaux O, et al. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. J Rheumatol. 2006;33:2464–2469.
   PubMed Web of Science ®Google Scholar
• Stack J, McLaughlin P, Sinnot C, et al. Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone. Scan J Rheumatol. 2010;39(4):349–350.
   PubMed Web of Science ®Google Scholar
• Valeur NS, Stevens AM, Ferguson MR, et al. Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol. 2015;204(2):408–422.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, doubleblind placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970.
   PubMed Web of Science ®Google Scholar
• Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133:455–460.
   PubMed Web of Science ®Google Scholar
• Liossis SNC, Bounas A, Andonopoulos A. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology. 2006;45:1005–1008.
   PubMed Web of Science ®Google Scholar
• Lafyatis R, O’Hara C, Feghali-Bostwick CA, et al. B-cell infiltration in systemic sclerosis – associated interstitial lung disease. Arthritis Rheum. 2007;56:3167–3168.
   PubMed Web of Science ®Google Scholar
• Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open label clinical and histopatological study. Ann Rheum Dis. 2010;69:193–197.
   PubMed Web of Science ®Google Scholar
• Layaftis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60:578–583.
   PubMed Web of Science ®Google Scholar
• Smith V, Piette Y, Van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52–57.
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–1194.
   PubMed Web of Science ®Google Scholar
• Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum. 1999;42:807–811.
   PubMed Web of Science ®Google Scholar
• Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. Jama. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• De Cruz S, Ross D. Lung transplantation in patients with scleroderma. Curr Opin Rheumatol. 2013;25:714–718.
   PubMed Web of Science ®Google Scholar